News

Scientists report a rare case of coexisting APC and KRAS mutations in a woman with familial adenomatous polyposis and prior endometrial cancer, highlighting a potential genetic synergy in multi-organ ...
During a live event, Christine Bestvina, MD, reviewed outcomes from the phase 3 KRYSTAL-12 and CodeBreak 200 trials in the ...
The “Research Spotlight” series is written by Dr. Anna Berkenblit, PanCAN’s Chief Scientific and Medical Officer. Each month, ...
Researchers have discovered an unusual case where two well-known cancer-related mutations—APC and KRAS—coexisted in a woman with familial adenomatous ...
Researchers have discovered an unusual case where two well-known cancer-related mutations-APC and KRAS-coexisted in a woman with familial adenomatous polyposis (FAP) and a history of endometrial ...
The global market for KRAS inhibitors has seen substantial growth in recent years, largely due to the heightened awareness of KRAS mutations as significant contributors to cancer development in ...
The response rate was higher in those with a KRAS mutation at 44%, compared to 17% in KRAS wild-type patients.
Lung cancer, traditionally linked to smoking, is increasingly affecting non-smokers due to factors like air pollution, radon exposure, and secondhand ...
Breakthrough Therapy Designation granted to elironrasib for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer who have received prior ...
Verastem's FDA approval for KRAS-mutant LGSOC, strong pipeline, and catalysts signal growth potential. Click here to read an ...
Castle Biosciences' DecisionDx-Melanoma test and Revolution Medicines' elironrasib cancer drug receive FDA Breakthrough ...